Guardant Health (GH) Stock Analysis & Winston Score
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asym
Winston Score: 21/100 — Weak
Weak fundamentals across most pillars.
- Quality: Mixed (8/30)
- Growth: Mixed (6/20)
- Cash Flow: Weak (0/10)
- Stability: Data not available (0/10)
- Valuation: Data not available (0/10)
- Ownership: Mixed (6/15)
Key Facts
Price: $155.87
Market Cap: $20.7B
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Exchange: NASDAQ
